In those taking [[sulphonylurea]]s there is an increased risk of [[hypoglycemia|low blood sugar]].<ref>{{cite journal|last1=Salvo|first1=Francesco|last2=Moore|first2=Nicholas|last3=Arnaud|first3=Mickael|last4=Robinson|first4=Philip|last5=Raschi|first5=Emanuel|last6=De Ponti|first6=Fabrizio|last7=Bégaud|first7=Bernard|last8=Pariente|first8=Antoine|title=Addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: systematic review and meta-analysis|journal=BMJ|date=3 May 2016|pages=i2231|doi=10.1136/bmj.i2231|pmid=27142267|pmc=4854021|volume=353}}</ref>

 


 
3 adverse reactions were seen higher in saxagliptin vs placebo.

 
Table 1: Adverse Reactions (Regardless of Investigator Assessment of Causality) in Placebo-Controlled Trials* Reported in ≥ 5% of Patients Treated with ONGLYZA (saxagliptin tablets) 5&nbsp;mg and More Commonly than in Patients Treated with Placebo.<ref name = rxlist>{{cite web | publisher = RxList | title = Onglyza | url = http://www.rxlist.com/onglyza-drug.htm | accessdate = 2012-01-31}}</ref>

 
{| class="wikitable" style="margin: 1em auto 1em auto;"

 
|+ '''Number (%) of Patients'''

 
! scope="col" | 

 
! scope="col" | ONGLYZA 5&nbsp;mg N=882 

 
! scope="col" | Placebo N=799

 
|-

 
| Upper respiratory tract infection  || 68 (7.7) || 61 (7.6)

 
|-

 
| Urinary tract infection || 60 (6.8) || 49 (6.1)

 
|-

 
| Headache || 57 (6.5) || 47 (5.9)<ref name = rxlist/>

 


 
|}

 


 
* The 5 placebo-controlled trials include two monotherapy trials and one add-on combination therapy trial with each of the following: metformin, thiazolidinedione, or glyburide. Table shows 24-week data regardless of glycemic rescue.<ref name = rxlist/>

 


 
In February 2012, Bristol-Myers/Astra Zeneca distributed additional safety information on saxagliptin use in South Africa. The package insert is to be edited for South Africa. Contraindications will now include a history of sensitivity to saxagliptin (or another DPP4 inhibitor) as well as pancreatitis. Spontaneously-reported adverse events in South Africa have included anaphylaxis, angioedema and acute pancreatitis.

 


 
In a cardiovascular outcomes trial, saxagliptin treatment let to a small increase in the risk of being hospitalized for heart failure.<ref name="Sci2013"/> They may cause severe joint pain.<ref>{{cite web|title=DPP-4 Inhibitors for Type 2 Diabetes: Drug Safety Communication - May Cause Severe Joint Pain|url=http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm460238.htm|website=FDA|accessdate=1 September 2015|date=2015-08-28}}</ref>

 


 
On April 14, 2015, an FDA advisory panel voted 14-1 in favor of adding information about heart failure risks to the label of saxagliptin.<ref>{{Cite web|url=http://www.medscape.com/viewarticle/843179|title=FDA Panel Backs New Safety Warnings on Two Diabetes Drugs|last=Ault|first=Alicia|date=April 14, 2015|website=Medscape Pharmacists|publisher=|access-date=July 21, 2016}}</ref>

 

